74128
document
Mexiletine for treatment of chronic painful diabetic neuropathy . Sixteen of nineteen patients completed a randomised double-blind crossover trial to assess the effect of oral mexiletine ( 10 mg/kg bodyweight daily ) on the symptoms and signs of chronic painful diabetic neuropathy . The median age of the sixteen patients was 50 years ( range 30-64 ) . Assessment with a five-item clinical symptom scale showed significant improvement during the mexiletine phase compared with the placebo phase . Pain was reduced during mexiletine but not during placebo , as assessed by a visual analogue rating scale . Mexiletine treatment had no effect on tendon reflexes , vibration threshold levels , beat-to-beat variation in heart rate during deep breathing , and postural blood pressure response . Mild side-effects were seen in three of the sixteen patients during mexiletine treatment .
74129
Intervention_Pharmacological
Mexiletine
74130
Intervention_Pharmacological
oral mexiletine
74131
Intervention_Control
placebo
74132
Intervention_Pharmacological
mexiletine
74133
Intervention_Control
placebo
74134
Intervention_Pharmacological
Mexiletine
74135
Outcome_Other
five-item clinical symptom scale
74136
Outcome_Pain
Pain
74137
Outcome_Physical
tendon reflexes
74138
Outcome_Physical
vibration threshold levels
74139
Outcome_Physical
beat-to-beat variation in heart rate during deep breathing
74140
Outcome_Physical
postural blood pressure response
74141
Outcome_Adverse-effects
Mild side-effects